Insider Transactions in Q1 2024 at Ocular Therapeutix, Inc (OCUL)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2024
|
Richard L Md Lindstrom Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,302
+9.49%
|
$242,416
$8.8 P/Share
|
|
Feb 26
2024
|
Summer Road LLC |
BUY
Open market or private purchase
|
Indirect |
930,851
+9.78%
|
$6,515,957
$7.52 P/Share
|
|
Feb 22
2024
|
Sanjay Nayak Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,300
+30.81%
|
-
|
|
Feb 22
2024
|
Pravin Dugel Director |
BUY
Grant, award, or other acquisition
|
Direct |
854,979
+50.0%
|
-
|
|
Feb 05
2024
|
Philip C. Strassburger General Counsel |
BUY
Open market or private sale
|
Direct |
6,029
+3.6%
|
$24,116
$4.86 P/Share
|
|
Feb 05
2024
|
Christopher G White Chief Business Officer |
BUY
Open market or private sale
|
Direct |
5,910
+4.56%
|
$23,640
$4.86 P/Share
|
|
Feb 05
2024
|
Donald Notman Officer |
BUY
Open market or private sale
|
Direct |
6,212
+3.08%
|
$24,848
$4.86 P/Share
|
|
Feb 05
2024
|
Rabia Gurses Ozden Chief Medical Officer |
BUY
Open market or private sale
|
Direct |
6,346
+3.98%
|
$25,384
$4.86 P/Share
|
|
Feb 05
2024
|
Antony C. Mattessich President and CEO |
BUY
Open market or private sale
|
Direct |
19,642
+3.23%
|
$78,568
$4.86 P/Share
|
|
Feb 03
2024
|
Philip C. Strassburger General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
58,304
+25.82%
|
-
|
|
Feb 03
2024
|
Christopher G White Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,980
+23.58%
|
-
|
|
Feb 03
2024
|
Donald Notman Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,636
+23.42%
|
-
|
|
Feb 03
2024
|
Rabia Gurses Ozden Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,633
+29.48%
|
-
|
|
Feb 03
2024
|
Antony C. Mattessich President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
180,400
+22.87%
|
-
|
|
Jan 31
2024
|
Antony C. Mattessich President and CEO |
SELL
Open market or private sale
|
Direct |
18,338
-4.11%
|
$73,352
$4.95 P/Share
|
|
Jan 31
2024
|
Christopher G White Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,147
-5.43%
|
$20,588
$4.95 P/Share
|
|
Jan 31
2024
|
Philip C. Strassburger General Counsel |
SELL
Open market or private sale
|
Direct |
6,831
-5.89%
|
$27,324
$4.95 P/Share
|
|
Jan 31
2024
|
Rabia Gurses Ozden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,764
-7.72%
|
$31,056
$4.95 P/Share
|
|
Jan 31
2024
|
Donald Notman Officer |
SELL
Open market or private sale
|
Direct |
6,433
-4.4%
|
$25,732
$4.95 P/Share
|